Dopaminergic effects on simple and choice reaction time performance in Parkinson’s disease

Neurology

Volumn 38, Issue 2, 1988, Pages 249-254

  Pullman, S L ^a   Watts, R L ^a   Juncos, J L ^b   Chase, T N ^b   Sanes, J N ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LEVODOPA;

INTRAVENOUS DRUG ADMINISTRATION; PARKINSON DISEASE; PRIORITY JOURNAL; REACTION TIME;

ADULT; AGED; FEMALE; HUMAN; LEVODOPA; MALE; MIDDLE AGE; PARKINSON DISEASE; PSYCHOMOTOR PERFORMANCE; REACTION TIME;

EID: 0023858101     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/wnl.38.2.249     Document Type: Article

References (24)

1. Evarta EV, Teräväinen H, Calne DB. Reaction time in Parkinson’s disease. Brain 1981;104:167–186.
2. Rafal RD, Posner MI, Walker JA, Friedrich FJ. Cognition and the basal ganglia. Brain 1984;107:1083–1094.
3. Bloxham CA, Mindel TA, Frith CD. Initiation and execution of predictable and unpredictable movements in Parkinson’s disease. Brain 1984;107:371–384.
4. Yokochi F, Nakamura R, Narabayashi H. Reaction time of patients with Parkinson’s disease, with reference to asymmetry of neurological signs. J Neurol Newurg Psychiatry 1985;48:702–705.
5. Heilman KM, Bowers D, Watson RT, Greer M. Reaction times in Parkinson’s disease. Arch Neurol 1976;33:139–140.
6. Wilson SAK. Some disorders of motility and of muscle tone, with special reference to the corpus striatum. Lancet 1925;2:1–10, 53–62,169–178, 215–219, 266–276.
7. Hoehn MM, Yahr MD. Parkinsonism: onset, progression, and mortality. Neurology 1967;17:427–444.
8. Duvoisin RC. The evaluation of extrapyramidal disease. In: de Ajuriaguerra J, Gauthier G, eds. Monamines, noyaux gris centraux et syndrome de Parkinson. Park Masson, 1971:313–325.
9. Wagner J, Vitali P, Palfreyman MG, Zraika M, Hunt S. Simultaneous determination of L-dopa, 5-HT, dopamine, 4-hydroxy-3-methoxy-phenylalanine, norepinephrine, DOPAC, HVA, serotonin, and 5-HIAA in rat cerebrospinal fluid and brain by high performance liquid chromatography with electrochemical detection. J Neurochem 1982;38:1241–1254.
10. Hallett M, Khoshbin S. A physiological mechanism of bradykine-sia. Brain 1980;103:301–314.
11. Mareden CD. The mysterious motor function of the basal ganglia. Neurology 1982;32:514–539.
12. Velasco F, Velasco M. A quantitative evaluation of the effecte of L-dopa on Parkinson’s disease. Neuropharmacology 1973;12:89–99.
13. Alexander GE, DeLong MR, Strick PL. Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annu Rev Neurosci 1986;9:357–381.
14. Schell GR, Strick PL. The origin of thalamic inputs to the arcuate premotor and supplementary motor areas. J Neurosci 1984;4:539–560.
15. Tanji J, Taniguchi K, Saga T. Supplementary motor area: neuronal response to motor instructions. J Neurophysiol 1980;43:60–68.
16. Moore RY, Bloom FE. Central catecholamine neuron systems: anatomy and physiology of the norepinephrine and epinephrine systems. Annu Rev Neurosci 1979;2:113–168.
17. Hornykiewicz O. Brain neurotransmitter changes in Parkinson’s dim, chap 4. In: Marsden CD, Fahn S, eds. Movement disorders. Boston: Butterworth Scientific, 1982:41–58.
18. Stern Y, Mayeux R, Cote L. Reaction time and vigilance in Parkinson’s disease. Arch Neurol 1984;41:1086–1089.
19. Mason ST, Fibiger HC. Noradrenaline and selective attention. Life Sci 1979;25:1949–1956.
20. Steriade M, Glenn LL. Neocortical and caudate projections of intralaminar thalamic neurons and their synaptic excitation from midbrain reticular core. J Neurophysiol 1982;48:352–371.
21. Brooks VB. The neural basis of motor control. New York: Oxford University Press, 1986:290–315.
22. Taylor AE, Saint-Cyr JA, Lang AE. Frontal lobe dysfunction in Parkinson’s disease. Brain 1986;109:845–883.
23. Thierry AM, Tassin JP, Blanc G, Glowinski J. Studies on meso-cortical dopamine systems. Adv Biochem Psychopharmacol 1978;19:205–216.
24. Weinberger DR, Berman KF, Chase TN. Prefrontal cortex physiological activation: effect of L-dopa in Parkinson’s disease. Abstract. Neurology 1986;36(suppl 1):170.